No Data
No Data
CLSA PREMIUM: 2024 Interim Report
CLSA Premium Limited Reports Mid-Year Financials
CLSA PREMIUM (06877) announced its interim performance with a net profit of HKD 6.26 million, a year-on-year increase of 12.71%.
CLSA PREMIUM (06877) announced its mid-term business performance for 2024, with a total income from ongoing operations...
Express News | CLSA Premium H1 Net Income HKD 6.26 Million
CLSA PREMIUM: UNAUDITED INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
No Data
No Data